Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

Journal of Virology

Volumn 74, Issue 1, 2000, Pages 371-378

  Davis, Nancy L ^a   Caley, Ian J ^a   Brown, Kevin W ^a   Betts, Michael R ^a,e   Irlbeck, David M ^a   McGrath, Kathryn M ^b   Connell, Mary J ^c   Montefiori, David C ^d   Frelinger, Jeffrey A ^a   Swanstrom, Ronald ^a,b   Johnson, Philip R ^a,c   Johnston, Robert E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MACACA; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; REPLICON; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS LOAD; VIRUS PARTICLE;

EID: 0033988633     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.1.371-378.2000     Document Type: Article

References (50)

1. Almond, N. M., and J. L. Heeney. 1998. AIDS vaccine development in primate models. AIDS 12(Suppl. A):S133-S140.
2. Anderson, M. J., D. C. Porter, Z. Moldoveanue, T. M. Fletcher III, S. McPherson, and C. D. Morrow. 1997. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res. Hum. Retrovir. 13:53-62.
3. Baba, T. W., Y. S. Jeong, D. Penninck, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267:1820-1824.
4. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
5. Benson, J., C. Chougnet, M. Robert-Guroff, D. Montefiori, P. Markham, G. Shearer, R. C. Gallo, M. Cranage, E. Paoletti, K. Limbach, D. Venzon, J. Tartaglia, and G. Franchini. 1998. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251: dependence on route of challenge exposure. J. Virol. 72:4170-4182.
6. Berglund, P., M. Quesada-Rolander, P. Putkonen, G. Biberfeld, R. Thorstensson, and P. Liljestrom. 1997. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retrovir. 13:1487-1495.
7. Betts, M. R., J. F. Krowka, T. B. Kepler, M. Davidian, C. Christopherson, S. Kwok, L. Louie, J. Eron, H. Sheppard, and J. A. Frelinger. 1999. Human immunodeficiency virus type 1 cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res. Hum. Retrovir. 15:1219-1228.
8. Caley, I. J., M. R. Belts, D. M. Irlbeck, N. L. Davis, R. Swanstrom, J. A. Frelinger, and R. E. Johnston. 1997. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:3031-3038.
9. Charles, P. C., K. W. Brown, N. L. Davis, M. K. Hart, and R. E. Johnston. 1997. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology 228:153-160.
10. Clark, A., C. W. Potter, R. Jennings, J. P. Nicholl, A. F. Langrick, G. C. Schild, J. M. Wood, and D. A. Tyrrell. 1983. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J. Hyg. 90:351-359.
11. Clements, M. L., M. H. Snyder, A. J. Buckler-White, E. L. Tierney, W. T. London, and B. R. Murphy. 1986. Evaluation of avian-human reassortant influenza A/Washington/897/80 × A/Pintail/119/79 virus in monkeys and adult volunteers. J. Clin. Microbiol. 24:47-51.
12. Clements-Mann, M. L., K. Weinhold, T. J. Matthews, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, R. H. Hsieh, J. Meslecky, S. ZollaPazner, J. Mascola, D. Schwartz, R. Siliciano, L. Corey, P. F. Wright, R. Belshe, R. Dolin, S. Jackson, S. Xu, P. Fast, M. C. Walker, D. Stablein, J.-L. Excler, J. Tartaglia, E. Paoletti, et al. 1998. Immune responses to human immunodeficiency virus (HIV) tvpe I induced by canarypox expressing HIV-IMN gp120. HIV-ISF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177:1230-1246.
13. Cohen, J. 1997. Weakened SIV vaccine still kills. Science 278:24-25.
14. Conner, R. I., B. T. M. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, E. Fenamort, V. Cao, F. Gao, S. Kalams, K. J. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J. P. Moore, and S. M. Wolinsky. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
15. Davis, N. L., K. W. Brown, G. F. Greenwald, A. J. Zajac, V. L. Zacny, J. F. Smith, and R. E. Johnston. 1995. Attenuated mutants of Venezuelan equineencephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212:102-110.
16. Davis, N. L., K. W. Brown, and R. E. Johnston. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787.
17. Ferrari, G., W. Humphrey, M. J. McElrath, J.-L. Excler, A.-M. Duliege, M. L. Clements, L. C. Corey, D. P. Bolognesi, and K. J. Weinhold. 1997. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94:1396-1401.
18. Frolov, I., and S. Schlesinger. 1996. Translation of Sindbis virus mRNA: analysis of sequences downstream of the initiating AUG codon that enhance translation. J. Virol. 70:1182-1190.
19. Goldstein, S., W. R. Elkins, W. T. London. A. Hahn, R. Goeken, J. E. Martin, and V. M. Hirsch. 1994. Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J. Med. Primatol. 23:75-82.
20. Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki, and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206:994-1006.
21. Hahn, C. S., Y. S. Hahn, T. J. Braciale, and C. M. Rice. 1992. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc. Natl. Acad. Sci. USA 89:2679-2683.
22. Hevey, M., D. Negley, P. Pushko, J. Smith, and A. Schmaljohn. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251:28-37.
23. Hirsch, V. M., G. Dapolito, C. McGann, R. A. Olmsted, R. H. Purcell, and P. R. Johnson. 1989. Molecular cloning of SIV from sooty mangabey monkeys. J. Med. Primatol. 18:279-285.
24. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, Jr., W. R. Elkins, W. G. Alvord, D. C. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3751.
25. Hirsch, V. M., and P. R. Johnson. 1992. Pathogenesis of experimental SIV infection of macaques. Semin. Virol. 3:175-183.
26. Hirsch, V. M., and P. R. Johnson. 1994. Pathogenic diversity of simian immunodeficiency viruses. Virus Res. 32:183-203.
27. Hu, S.-L., K. Abrams, G. N. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton, and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.
28. Hu, S.-L., P. Polacino, V. Stallard, J. Klaniecki, S. Pennathur, B. M. Travis, L. Misher, H. Kornas, A. J. Langlois, W. R. Morton, and R. E. Benveniste. 1996. Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection. Immunol. Let. 51:115-119.
29. Jahrling, P. B., and E. H. Stephenson. 1984. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J. Clin. Microbiol. 19:429-431.
30. Kaplan, A. H., and R. Swanstrom. 1991. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. USA 88:4528-4532.
31. Kinney, R. M., J. J. Esposito, J. H. Mathews, B. J. B. Johnson, J. T. Roehrig, A. D. T. Barrett, and D. W. Trent. 1988. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J. Virol. 62:4697-1702.
32. Lifson, J., M. A. Nowak, S. Goldstein, J. L. Rossio, A. Kinter, G. Vasquez, T. A. Wiltrout, C. Brown, D. Schneider, L. Wahl, A. L. Lloyd, J. Williams, W. R. Elkins, A. S. Fauci, and V. M. Hirsch. 1997. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J. Virol. 71:9508-9514.
33. Liljestrom, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 9:1356-1361.
34. Lu, S., J. Arthos, D. C. Montefiori, Y. Yasutomi, K. Manson, F. Mustafa, E. Johnson, J. C. Santoro, J. Wissink, J. I. Mullins, J. R. Haynes, N. L. Letvin, M. Wyand, and H. L. Robinson. 1996. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:3978-3991.
35. Luckow, V. A., and M. D. Summers. 1988. Trends in the development of baculovirus expression vectors. Bio/Technology 6:47-55.
36. MacDonald, G. H., and R. E. Johnston. The role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol., in press.
37. Mackett, M., G. L. Smith, and B. Moss. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:857-864.
38. Matsui, M., C. E. Hioe, and J. A. Frelinger. 1993. Roles of the six peptidebinding pockets of the HLA-A2 molecule in allorecognition by human cytotoxic T-cell clones. Proc. Natl. Acad. Sci. USA 90:674-578.
39. Monath, T., C. H. Calisher, M. Davis, G. S. Bowen, and J. White. 1974. Experimental studies of rhesus monkeys infected with epizootic and enzootic subtypes of Venezuelan equine encephalitis virus. J. Infect. Dis. 129:194-200.
40. Montefiori, D., T. W. Baba, A. Li, M. Bilska, and R. M. Ruprecht. 1996. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J. Immunol. 157:5528-5535.
41. Mossman, S. P., F. Bex, P. Berglund, J. Arthos, S. P. O'Neil, D. Riley, D. H. Maul, C. Bruck, P. Momin, A. Burny, P. N. Fultz, J. I. Mullins, P. Liljestrom, and E. A. Hoover. 1996. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70:1953-1960.
42. Pialoux, G., J.-L. Excler, Y. Riviere, G. Gonzalez-Canali, V. Feuillie, P. Coulaud, J.-C. Gluckman, T. J. Matthews, B. Meignier, M.-P. kieny, P. Gonnet, I. Diaz, C. Meric, E. Paoletti, J. Tartaglia, H. Salomon, S. Plotkin, The AGIS Group, and L'Agence Nationale de Recherche sur le SIDA. 1995. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160(MN) followed by a recombinant glycoprotein 160(MN/LA1). AIDS Res. Hum. Retrovir. 11:373-381.
43. Polo, J. M., B. A. Belli, D. A. Driver, I. Frolov, S. Sherrill, M. J. Hariharan, K. Townsend, S. Perri, S. J. Mento, D. J. Jolly, S. M. W. Chang, S. Schlesinger, and T. W. Dubensky, Jr. 1999. Stable alphavirus packaging cell lines for Sindbis virus- and Semliki Forest virus-derived vectors. Proc. Natl. Acad. Sci. USA 96:4598-4603.
44. Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. Smith. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401.
45. Stott, E. J., and G. C. Schild. 1996. Strategies for AIDS vaccines. J. Antimicrob. Chemother. 37:185-198.
46. Stott, J., and S.-L. Hu. 1998. Vaccines and immunology. AIDS 12(Suppl. A):S95-S96.
47. Urdea, M. S., J. C. Wilber, T. Yeghiazarian, J. A. Todd, D. G. Kern, S.-J. Fong, D. Besemer, B. Hoo, P. J. Sheridan, R. Kokka, P. Neuwald, and C. A. Pachl. 1993. Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS 7(Suppl. 2):S11-S14.
48. Xiong, C., R. Levis, P. Shen, S. Schlesinger, C. M. Rice, and H. V. Huang. 1989. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243:1188-1191.
49. Zhou, S., P. Berglund, H. Zhao, P. Liljestrom, and M. Jondal. 1995. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl. Acad. Sci. USA 92:3009-3013.
50. Zhou, X., P. Berglund, G. Rhodes, S. E. Parker, M. Jondal, and P. Liljestrom. 1994. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12:1510-1514.